Reslizumab
- Generic Name
- Reslizumab
- Brand Names
- Cinqair, Cinqaero
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 241473-69-8
- Unique Ingredient Identifier
- 35A26E427H
- Background
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils . Elevated levels of eosinophi...
- Indication
Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
- Associated Conditions
- Severe Eosinophilic Asthma
- Associated Therapies
- -
Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT03369574
- Locations
- 🇺🇸
University of Rochester Department of Otolaryngology Head and Neck Surgery, Rochester, New York, United States
Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2018-05-16
- Target Recruit Count
- 30
- Registration Number
- NCT03074942
- Locations
- 🇪🇸
Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
🇪🇸Hospital de Sabadell, Sabadell, Barcelona, Spain
🇪🇸Hospital Universitari Son Espases, Palma, Islas Baleares, Spain
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT03052725
- Locations
- 🇺🇸
Teva Investigational Site 14651, Chicago, Illinois, United States
🇧🇪Teva Investigational Site 37083, Gent, Belgium
🇵🇱Teva Investigational Site 53399, Krakow, Poland
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 10
- Registration Number
- NCT02947945
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02937168
- Locations
- 🇺🇸
Teva Investigational Site 13808, New Brunswick, New Jersey, United States
Effect of Reslizumab in Chronic Rhinosinusitis
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Joshua S. Jacobs
- Target Recruit Count
- 30
- Registration Number
- NCT02799446
- Locations
- 🇺🇸
Allergy and Asthma Clinical Research, Walnut Creek, California, United States
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02501629
- Locations
- 🇺🇸
Teva Investigational Site 13349, Cincinnati, Ohio, United States
🇺🇸Teva Investigational Site 13357, Bakersfield, California, United States
🇺🇸Teva Investigational Site 13365, Long Beach, California, United States
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 468
- Registration Number
- NCT02452190
- Locations
- 🇺🇸
Teva Investigational Site 13215, Bakersfield, California, United States
🇺🇸Teva Investigational Site 13235, Shiloh, Illinois, United States
🇺🇸Teva Investigational Site 13208, Tallahassee, Florida, United States
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 511
- Registration Number
- NCT01508936
- Locations
- 🇺🇸
Investigational Site 865, Miami, Florida, United States
🇺🇸Investigational Site 881, Miami, Florida, United States
🇺🇸Investigational Site 809, Tucson, Arizona, United States
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1052
- Registration Number
- NCT01290887
- Locations
- 🇺🇸
Teva Investigational Site 53, Clearwater, Florida, United States
🇺🇸Teva Investigational Site 19, Tallahassee, Florida, United States
🇺🇸Teva Investigational Site 46, Bangor, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.